Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8607826 | 1.00 | ALDH1A1 (0.41) | ALDH1A1EGLN1TET2TGFBR1HCAR2 | |
| SCHEMBL8605808 | 1.00 | ALDH1A1 (0.41) | ALDH1A1EGLN1TET2TGFBR1HCAR2 | |
| SCHEMBL3185570 | 0.90 | ALDH1A1 (0.47) | ALDH1A1EGLN1TET2TGFBR1HCAR2 | |
| SCHEMBL823296 | 0.90 | ALDH1A1 (0.47) | ALDH1A1EGLN1TET2TGFBR1HCAR2 | |
| SCHEMBL7770999 | 0.90 | ALDH1A1 (0.47) | ALDH1A1EGLN1TET2TGFBR1HCAR2 | |
| SCHEMBL28386374 | 0.78 | — | — | |
| SCHEMBL15133568 | 0.77 | ALDH1A1 (0.38) | ALDH1A1EGLN1TET2TGFBR1 | |
| SCHEMBL126786 | 0.76 | — | — | |
| Oxalic Acid SCHEMBL21633322 | 0.76 | ALDH1A1 (0.47) | ALDH1A1EGLN1TET2TGFBR1HCAR2 | |
| SCHEMBL27713670 | 0.75 | ALDH1A1 (0.41) | ALDH1A1EGLN1TET2TGFBR1HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110105503-A | A kind of efficient diminishing polycarboxylate water-reducer of viscosity reduction type and preparation method thereof | 湖南大学 | 2019-08-09 | — | — | CN | disclosed |
| US-8859563-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2014-10-14 | — | — | US | disclosed |
| US-8859563-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2014-10-14 | — | — | US | disclosed |
| US-20120232035-A1 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-09-13 | — | — | US | disclosed |
| US-20120232035-A1 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232035-A1 | Bicyclic pyrimidinones and uses thereof | TPMT, TYMP, DPYD | ALDH1A1 337/4885EGLN1 1127/4885TET2 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.